Cancer Biotech Lixte Abandons Drug Identity to Acquire Battery Storage Company
Strategic Pivot
Company Background
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company whose principal asset is LB-100, a first-in-class PP2A inhibitor it describes as well-tolerated in cancer patients at doses associated with anti-cancer activity. Proof-of-concept trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. A wholly owned subsidiary, Liora Technologies Europe Ltd., is also developing electronically controlled proton therapy systems under the LiGHT System brand.
The company trades on the Nasdaq Capital Market under the ticker LIXT, with a market cap of approximately $132 million. No financial deterioration or going-concern language appears in the filings reviewed; the strategic shift appears to be a deliberate decision by management rather than a response to an acute financial crisis.
NOMAD Transportable Power Systems, the acquisition target, describes itself as the market leader in deployable, utility-grade battery energy storage systems (BESS) and claims to be the first company to bring a mobile, utility-grade 1 MW BESS to market. According to the press release accompanying the merger announcement, NOMAD's revenue grew approximately 175% year-over-year in 2025, with management projecting further growth of approximately 135% in 2026.
What Was Disclosed
A $6.5 million secured promissory note, issued by Lixte to NOMAD on June 17, 2026 — six days after the merger agreement was signed — is secured by a first-priority security interest in substantially all of NOMAD's assets. The note's proceeds serve two purposes: first, to repay in full NOMAD's outstanding obligations under a Loan and Security Agreement dated February 12, 2024, between NOMAD and BPCP Investment Holdings, LP (successor in interest to Bay Point Capital Partners II, LP), with that portion disbursed directly to BPCP by Lixte on NOMAD's behalf; and second, for NOMAD's working capital and general corporate purposes.
The note matures 30 days from issuance but automatically extends in 30-day increments as long as the Merger Agreement remains in effect and has not been terminated. If the merger closes, the outstanding principal is offset against amounts otherwise deliverable to NOMAD under Section 6.05 of the Merger Agreement. The termination mechanics are asymmetric: if Lixte breaches and the deal collapses, the note is repayable within six months; if NOMAD breaches, the note becomes due within three days.
The merger itself, announced June 11, provides NOMAD stockholders with up to 50,500 shares of newly designated Series D Convertible Preferred Stock — convertible into up to 50,500,000 shares of Lixte common stock at $1.00 per share — plus up to 3,000,000 shares of common stock directly. The preferred shares are non-voting until Lixte's stockholders separately approve the conversion. Closing is expected on or about July 1, 2026, and requires Lixte to hold at least $16.5 million in unrestricted cash at that time. Upon closing, the company will be renamed NOMAD Power Solutions, Inc. and will begin trading under a new ticker symbol.
Why It Matters
The transaction represents a complete identity change for Lixte: a clinical-stage oncology company with active human trials is stepping away from its drug pipeline to become a publicly traded vehicle for an energy infrastructure business. The filings do not explain why management chose to pursue this direction rather than continuing drug development, and it would be improper to speculate. What the documents do establish is that NOMAD carried an existing secured bank loan — in place since February 2024 with BPCP Investment Holdings — that Lixte moved to extinguish before the merger even closed, deploying $6.5 million and taking a first-priority lien on NOMAD's assets as protection during the interim period.
The potential dilution from the merger consideration is substantial relative to Lixte's current scale. Up to 50.5 million preferred-to-common conversion shares, plus 3 million direct common shares, could be issued at a $1.00 conversion price. Those shares cannot be voted until a separate stockholder meeting — required within 60 days of closing — approves the conversion; Lixte has also committed to file a resale registration statement within 30 days of receiving that approval, which would allow NOMAD's former stockholders to sell into the market.
The $16.5 million closing cash condition takes on added weight given that $6.5 million has already been deployed to NOMAD ahead of close. Whether Lixte can satisfy that threshold at closing while having already extended the pre-close loan is a structural question the filings do not resolve with available cash balance data. Investors will likely focus on Lixte's current cash position as the anticipated July 1 closing date approaches.
